Repare Therapeutics Inc. (Nasdaq: RPTX) shareholders have approved the acquisition by XenoTherapeutics, Inc.
The acquisition involves XenoTherapeutics, Inc. and Xeno Acquisition Corp., a non-profit biotechnology company
The approval was granted at a special meeting of shareholders, where a special resolution approving the arrangement was passed
Acquisition Approval
Shareholders approved the acquisition of all issued and outstanding common shares by XenoTherapeutics, Inc.
Vote Ratification
The special resolution for the arrangement was approved by 99.76% of votes cast by shareholders present at the meeting
Compensation Approval
Compensation for named executive officers related to the arrangement was approved on an advisory basis
- The completion of the acquisition is subject to the approval of the Superior Court of Québec
- Assuming all conditions are met, the acquisition is expected to be completed around January 28, 2026
The approval of Repare Therapeutics' acquisition marks a significant step in its strategic development and future collaboration with XenoTherapeutics, Inc.